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Survey of Surgical Infections Currently Known (SOSICK):
A Multicenter Examination of Antimicrobial Use from the
Surgical Infection Society Scientific Studies Committee
Nicholas Namias,1 Jonathan P. Meizoso,2 David H. Livingston,3 and the SOSICK Investigators Group

Abstract

Purpose: The Scientific Studies Committee of the Surgical Infection Society undertook the present study to examine the prevalence of and indications for antimicrobial use in intensive care units where members of the Society practice.
Methods: Information and data collection sheets were posted on the Internet for download by members interested in participating. All centers were required to obtain approval from their local human subjects research
office or equivalent. A one-week time was set during which the center could collect information on any one
day, at the center’s convenience. Data collection sheets were then sent to the lead author for analysis. Seventeen centers reported data for 371 patients in 22 intensive care units.
Results: Trauma and general surgical patients comprised 224 of the patients (60%). The indications for anti-infective agents were prophylactic (22%), empiric (27%), therapeutic with known pathogen (41%), therapeutic
without known pathogen (e.g., cellulitis) (4%), insistence of influential practitioner (4%), or non-anti-infective
purposes (e.g., erythromycin for gastric motility) (2%). Only 44%, 29%, and 54% of the orders for prophylactic,
empiric, and therapeutic antibiotics, respectively, had date-certain stop dates. The antimicrobial drugs most
commonly used were vancomycin, piperacillin-tazobactam, and fluconazole.
Conclusion: Most patients were receiving antimicrobial agents. Polypharmacy was common. Most patients did
not have a date-certain stop date. This study sets the benchmark for future study regarding antibiotic prescribing behavior in surgical intensive care units.

T

abounds with reports of
overuse and inappropriate use of antimicrobial agents.
The general public has become aware of the issues of antimicrobial resistance and the potential for a return to the “preantibiotic” era. Intensive care units (ICUs) are known for
their high antibiotic utilization and as areas of high prevalence of antibiotic resistance [1,2]. The Scientific Studies
Committee of the Surgical Infection Society undertook the
present study to examine the prevalence of and indications
for antimicrobial use in ICUs where members of the Surgical Infection Society practice.
HE PROFESSIONAL AND LAY PRESS

to the membership. Information and data collection sheets
were posted on the Internet for download by members interested in participating (Appendix 1). All centers were required
to obtain approval from their local human subjects research
office or equivalent. A one-week time was set during which
the center could collect information on any one day, at the
center’s convenience. Data collection sheets were then sent to
the lead author for analysis. Seventeen centers reported data
for 371 patients in 22 intensive care units. Descriptive statistics are presented.
Results

Patients and Methods
A call for participation was made by an e-mail announcement from the central offices of the Surgical Infection Society

Table 1 shows the types of ICUs reporting, with the number of patients from each type. Table 2 shows the types of
patients enrolled. Trauma and general surgical patients comprised 224 of the 371 patients (60%). Eleven other specialties
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TABLE 1.

TYPES

Type of ICU
Burn
Cardiac
Med/surg
Neuro
Neurotrauma
Surgical
Trauma
Not specified
Total

OF

ICUS REPORTING,

WITH

NUMBER

OF

PATIENTS

FROM

EACH TYPE

Number
of units

Number
of patients

Number receiving
anti-infective agents

2
1
6
1
1
11
8
1
31

6
13
43
10
10
195
92
2
371

4
6
32
4
10
139
69
2
266

Med/surg  medical surgical; neuro  neurosurgical.

accounted for the remaining 40%, none of which was  10%
of the entire patient population. Forty-five patients (12%)
were hospitalized for cancer; 34 of them were receiving at
least one anti-infective agent. Twenty-eight (8%) were receiving transplant immune suppression; all 28 were receiving at
least one anti-infective agent. Figure 1 shows the distribution of the number of anti-infective agents per patient.
Seventy-two percent were on at least one anti-infective drug.
Anti-infective agents and the number of patients receiving them are seen in Table 3. The indications for the agents
were prophylactic (22%), empiric (27%), therapeutic with
known pathogen (41%), therapeutic without known pathogen (e.g., cellulitis) (4%), insistence of influential practitioner
(4%), or non-anti-infective purposes (e.g., erythromycin for
gastric motility) (2%). Antibiotics ordered without a clear indication, but at the insistence of an influential practitioner,
consisted of 13 drugs. Three of these (imipenem-cilastatin,
metronidazole, and piperacillin-tazobactam) made up nine
of the 20 (45%) orders for anti-infective agents at the behest
of an influential practitioner.
The indications for the antimicrobials most commonly ordered are shown in Table 4. The percentage of antibiotic orders with a certain stop date, stratified by indication, is seen
TABLE 2.

TYPES OF PATIENTS ENROLLED, WITH NUMBER
RECEIVING ANTI-INFECTIVE AGENTS

Type of patient
Burn
Cardiac/thoracic
ENT
General surgical
Urology
Gynecology-oncology
Medical
Neuro
Ortho
Spine
Transplant
Trauma
Vascular
Not specified
Total

Number

Number receiving
anti-infective agents

9
32
5
91
3
1
15
25
6
2
29
133
13
7
371

5
18
5
69
3
1
10
14
4
2
28
96
6
5
266

ENT  ear, nose, and throat; neuro  neurosurgery; ortho 
orthopedic surgery.

in Figure 2. Non-anti-infective use of anti-infective drugs was
uncommon, being limited to five patients receiving erythromycin for gastric motility, all from one center. No patients
were receiving fluconazole to increase serum tacrolimus concentrations.
Organisms causing infection can be seen in Figure 3 as a
percentage of all organisms. Specific organisms are listed in
Table 5.

Discussion
Antibiotic use has come under scrutiny in recent years as
part of the measure of the quality of surgical and medical
care [3–5]. Professional societies promulgate guidelines for
optimal use of antimicrobial drugs, our Surgical Infection Society included [6–14]. There are no standard guidelines for
the use of antimicrobials in the ICU setting, but there are
principles, some mutually contradictory, that are commonly
accepted. There are no Class 1 data to direct how antimicrobials should be used in the ICU. Differing schools of
thought recommend early broad-spectrum empiric antibiotics vs. withholding of antibiotics until infection is proved;
restraint in the use of vancomycin vs. liberal use of vancomycin in areas where the prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) is high; early empiric antifungal use when risk factors are present vs. withholding of antifungal use until fungal infection is proved, and so on, with
various degrees of less-than-Class 1 data in support of the
recommended practices. The fact is, we do not know how
best to use antibiotics in the ICU. It seemed that a survey of
how much, what, and why would be a reasonable place to
start to gain a better understanding of what the agenda ought
to be in the design of future trials of antimicrobial use in the
ICU.
The snapshot study was designed to capture a “day in the
life” in the ICUs of members of the Surgical Infection Society. The members of the study group reporting the data did
not necessarily direct all, or even any, of the antimicrobial
use. We did not collect data regarding who was responsible
for the management of antibiotic use, except for the one question that asked if the indication for an antibiotic was the desire of an influential practitioner, as opposed to a rational
medical indication. Four percent of antimicrobial use on the
study day was attributable to the insistence of an influential
practitioner, without a clear medical indication. Although
this number seems low, it probably would not seem so to a
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FIG. 1. Distribution of number of anti-infective agents per
patient; 71% received at least one.

TABLE 3.

ANTI-INFECTIVE DRUGS

AND

quality-seeking public. Four percent is too much: We need
to approach zero.
Two hundred fifty-three of the 391 patients (65%) were receiving antimicrobial drugs on the study day. Thirty-six percent of these drugs were being given for therapeutic reasons,
with a known organism. This use of anti-infective agents
probably is justified. By contrast, 32% of the antibiotics were
given empirically; it is hard to know if this use is justified.
There is intellectual disagreement among the members of the
SOSICK Study Group regarding the appropriate indications
for empiric antibiotics, and guidelines are needed.
Twenty-three percent of the antibiotics given were for prophylaxis. This number is worrisome. The only indication for
which we have data that prophylaxis is effective is in the perioperative surgical situation. These data support a single dose
of prophylactic antibiotic prior to operation, and the Surgical
Care Improvement Project (SCIP) guidelines allow for as long
as 24 to 48 h of postoperative prophylaxis in some cases. If one
in five of the patients in the ICUs studied had been in the im-

NUMBER

OF

PATIENTS RECEIVING EACH
No.
of patients

Drug
Vancomycin
Piperacillin-tazobactam
Fluconazole
Cefazolin
Linezolid
Metronidazole
Ciprofloxacin
Imipenem-cilastatin
Cefepime
Trimethoprim-sulfamethoxazole, levofloxacin, ganciclovir,
caspofungin, clindamycin, gentamicin, ceftriaxone
Ampicillin-sulbactam, erythromycin, tobramycin, valganciclovir,
amphotericin B lipid complex, clotrimazole, colistin, meropenem
Ampicillin, ertapenem, moxifloxacin, piperacillin, aztreonam,
cefoxitin, tigecycline, cloxacillin, oxacillin, rifampin, acyclovir,
amoxicillin, anidulafungin, azithromycin, cefotaxime, ceftazidime,
dapsone, daptomycin, doxycycline, itraconazole, micafungin,
minocycline, nystatin, penicillin G, sulbactam, ticarcillin-clavulanic
acid, voriconazole

TABLE 4.

INDICATIONS

Drug
Vancomycin
Piperacillin-tazobactam
Fluconazole
Cefazolin
Linezolid
Metronidazole
Ciprofloxacin
Imipenem or meropenem
Cefepime

FOR

69
63
42
28
25
24
22
20
16
10–15
5–9
5

ANTIMICROBIALS USED MOST COMMONLY

No.
of orders

Prophylactic
use

Empiric
use

Therapeutic
use

69
63
42
28
25
24
22
25
16

4
2
16
22
0
1
3
10
0

33
30
8
3
6
11
10
13
6

29
28
16
3
18
8
8
8
9

Number of orders is less than the sum of columns because of antimicrobial use for indications other
than prophylctic, empiric, or therapeutic.
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TABLE 5.

FIG. 2. Percentage of antibiotic orders with certain stop
date, stratified by indication. (Proph  prophylactic; Emp 
empiric; Ther  therapeutic.)
mediate perioperative period, then having 23% receiving prophylactic antibiotics would be reasonable. However, a large
percentage of the orders for prophylactic antibiotics did not
have a date-certain stop date, suggesting this use was not perioperative. Further study is needed to understand the use of
antibiotics for prophylactic reasons in the ICU.
The subgroups of cancer and transplant patients were analyzed separately because they may reasonably be expected
to have a pattern of antimicrobial utilization different from
that in the general population. It turned out this was not true
for cancer patients, but was true of transplant patients. All
transplant patients were receiving at least one antimicrobial
agent. Antimicrobial use in transplant patients is a field in
desperate need of more research.

FIG. 3. Organisms causing infection, as percentage of all
organisms. (Cdiff  Clostridium difficile; GNR  gram-negative bacilli; GPC  gram-positive cocci.)

ORGANISMS CAUSING INFECTION

Organism

No.

Staphylococcus spp.
Candida spp.a
Pseudomonas spp.
E. coli
Enterococcus spp.
Enterobacter spp.
Klebsiella spp.
Actinobacter spp.
Clostridium difficile
Proteus spp.
Haemophilus spp.
GNB NOSb
Stenotrophomonas maltophilia
Serratia spp.
Streptococcus spp.
Corynebacterium spp.
Moraxella spp.
Lactobacillus
Histoplasma
Burkholderia cepacia
Bacillus fragilis
Bacillus thiuringienesis
Citrobacter

41
20
14
13
13
11
9
9
5
4
4
4
4
3
3
2
1
1
1
1
1
1
1

aTen C. albicans, four Candida not otherwise specified, two C.
glabrata, two “yeast,” one “fungus,” one C. parapsilosis.
bGram-negative bacillus, not otherwise specified.

What antimicrobials are we using? The single most-commonly used antimicrobial was vancomycin, a 50-year-old
drug long off patent that requires monitoring of the serum
concentration. This is consistent with the fact that most of
the infections being treated were caused by gram-positive
cocci (GPC). Another agent active only against GPC (linezolid) was the fifth most commonly used agent. Daptomycin
was used in only one patient (data shown as part of the 0–5
group), and quinupristin-dalfopristin was not in use in any
of the study centers on the snapshot day. The respective roles
of the various focused anti-gram-positive agents have yet to
be defined clearly.
Piperacillin-tazobactam was the second most-commonly
used agent. This is logical in light of the fact that the second and third most common groups of organisms isolated
were gram-negative bacilli as a group and Pseudomonas. Although this finding may be interpreted as overuse of a
broad-spectrum agent, it may also be seen as good antibiotic stewardship in that it reflects restraint in the use of carbapenems.
Fluconazole was the third most-commonly used agent, reflecting the changing ecology of ICU infection. The use of
amphotericin preparations, echinocandins, and other azole
drugs was remarkably low in comparison to the stalwart fluconazole. It is notable that in the ICUs surveyed, of the 16
antibiotics used at least 10 times, 10 are off-patent, generically available drugs. The scrutiny of the effects of marketing on physician prescribing behavior appears to be misguided when applied to surgical critical care populations.
There are substantial limitations to a survey study. Data
were self-reported, and therefore subject to bias or misinterpretation of the definitions. We also do not have data
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TABLE 6.

Charles Adams, MD
Gregory J. Beilman, MD
Walter Biffl, MD
Juan J. Blondet, MD
Patrick Blute
Jessica Bollinger, PharmD
Susan A. Brundage, MD, MPH
Jeffrey G. Chipman, MD
Jeffrey A. Claridge, MD
Raul Coimbra, MD, PhD
Charles H. Cook, MD
Joseph Cuschieri, MD
Daniel L. Dent, MD
Lynn Derting, RN, BSN
Shaleagh Earl, RN
Anthony Gerlach, PharmD
Laura Hennessy, RN
Jeanne Lee, MD
Yanumei Li
Pamela Lipsett, MD
David H. Livingston, MD
Frederick Luchette, MD
John E. Mazuski, MD
Chet A. Morrison, MD
Nicholas Namias, MD
Claudio Nunes, MD
Kim Overton, RN
Mary-Ann Purtill, MD
Marline Santos
Orla N. Smith, RN, MN
Sandy Swoboda, RN MN
Hieu Ton That, MD
Shirin Towfigh, MD
Wael N. Yacoub, MD
Charles J. Yowler, MD

MEMBERS

OF THE

SOSICK INVESTIGATORS GROUP

Rhode Island Hospital, Providence
University of Minnesota Medical Center, Minneapolis
Rhode Island Hospital, Providence
University of Minnesota Medical Center, Minneapolis
St. Michael’s Hospital, Toronto
The Ohio State University College of Medicine and Public Health, Columbus
Stanford University Medical Center, Palo Alto
University of Minnesota Medical Center, Minneapolis
MetroHealth Medical Center Case Western Reserve University, Cleveland
University of California San Diego Medical Center
The Ohio State University College of Medicine and Public Health, Columbus
University of Washington Harborview Medical Center, Seattle
The University of Texas Health Science Center at San Antonio
University of Florida Health Science Center Jacksonville
Rhode Island Hospital, Providence
The Ohio State University College of Medicine and Public Health, Columbus
University of Washington Harborview Medical Center, Seattle
University of California San Diego Medical Center
St. Michael’s Hospital, Toronto
Johns Hopkins University, Baltimore
University of Medicine and Dentistry of New Jersey Medical School, Newark
Loyola University Medical Center, Maywood
Washington University School of Medicine, St. Louis
Michigan State University, East Lansing
University of Miami Miller School of Medicine
The University of Texas Health Science Center at San Antonio
The University of Texas Health Science Center at San Antonio
Stanford University Medical Center, Palo Alto
St. Michael’s Hospital, Toronto
St. Michael’s Hospital, Toronto
Johns Hopkins University, Baltimore
Rhode Island Hospital, Providence
Los Angeles County University of Southern California Medical Center
Los Angeles County University of Southern California Medical Center
MetroHealth Medical Center, Case Western Reserve University, Cleveland

on the specific diagnoses, the resistance patterns at each
institution, or the formulary pressures placed on practitioners at each center. Despite these limitations, we believe
this survey provides a baseline understanding of how we
are using antibiotics, and can be used for hypothesis generation.
In summary, we have found that (1) most patients in the
surveyed ICUs were receiving antimicrobial agents on the
snapshot day, with patients receiving more than one antimicrobial outnumbering those on only one; (2) vancomycin,
piperacillin-tazobactam, and fluconazole were the agents
most commonly used, reflecting the ecology of the organisms infecting our patients; (3) gram-negative bacilli, when
Pseudomonas spp. are included, and GPC, are most common
and similar in frequency; (4) fungi account for a substantial
portion of our infections; (5) prophylactic and empiric use of
antimicrobials is high, and further study is needed to determine if this use is appropriate; and (6) stop dates are not
present in a large number of cases. This study sets a benchmark for future investigation regarding antibiotic prescribing behavior in surgical ICUs.
Acknowledgment
This study would not have been possible without the participation of the SOSICK Investigator’s Group (Table 6).

References
1. Evans HL, Lefrak SN, Lyman J, et al. Cost of gram-negative
resistance. Crit Care Med 2007;35:89–95.
2. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated
pneumonia: Breaking the vicious circle of antibiotic overuse.
Crit Care Med 2007;35:379–385.
3. Khuri SF, Daley J, Henderson W, et al. The Department of
Veterans Affairs’ NSQIP: The first national, validated, outcome-based, risk-adjusted, and peer-controlled program for
the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg 1998;228:491–507.
4. Main DS, Henderson WG, Pratte K, et al. Relationship of
processes and structures of care in general surgery to postoperative outcomes: A descriptive analysis. J Am Coll Surg
2007;204:1157–1165.
5. Rowell KS, Turrentine FE, Hutter MM, et al. Use of National
Surgical Quality Improvement Program data as a catalyst for
quality improvement. J Am Coll Surg 2007;204:1293–1300.
6. Barie PS. Breaking with tradition: Evidence-based antibiotic
prophylaxis of open fractures. Surg Infect 2006;7:327–329.
7. Goldner JL. CDC guideline for the prevention of surgical site
infection. Surg Infect 2000;1:249–250.
8. Hauser CJ, Adams CA Jr, Eachempati SR. Surgical Infection Society guideline: Prophylactic antibiotic use in open fractures:
An evidence-based guideline. Surg Infect 2006;7:379–405.

514

NAMIAS ET AL.

9. Lee JT. A new surgical site infection (SSI) prevention guideline. Surg Infect 2000;1:127–131.
10. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect 2002;3:175–233.
11. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect 2002;3:161–173.
12. Dellinger EP, Gross PA, Barrett TL, et al. Quality standard
for antimicrobial prophylaxis in surgical procedures. The Infectious Diseases Society of America. Infect Control Hosp
Epidemiol 1994;15:182–188.

APPENDIX 1.

13. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the
management of intravascular catheter-related infections. J
Intraven Nurs 2001;24:180–205.
14. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the
selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997–1005.

Address reprint requests to:
Dr. Nicholas Namias
P.O. Box 016960 (D-40)
Miami, FL 33101
E-mail: nnamias@miami.edu

DATA COLLECTION SHEET

1. What type of ICU is this patient in?
a. Surgical

b. Med/Surg

c. Transplant

d. Trauma

e. Burn

f. Cardiac

g. Neuro

h. Other, please explain

2. Type of patient:
a. General surgical, not listed below

b. Trauma

c. Burn

d. Transplant

e. Neuro

f. Cardiac/thoracic

g. Vascular

h. ENT

i. Medical

j. Other, please explain

3.
4.
5.
6.

Is this patient hospitalized for a diagnosis of cancer (Y/N)?
Is this patient on immunosuppressant medication for transplantation (Y/N)?
Are any systemic (not topical) antibiotics/antifungas/antivirals ordered for today (Y/N)?
List anti-infective drugs and organisms below, and choose an indication from the following for each bug/drug
combination.
a. Prophylactic (strictly trying to prevent an infection)
b. Empiric (high suspicion of infection, may have clinical signs, or Gram stain, or preliminary broad result, e.g.,
“GNR”)
c. Therapeutic (known pathogen)
d. Therapeutic (known infection but pathogen not identifiable, as in cellulitis)
e. Fits none of the above, but influentia practitioner insists, with free text collection of the argument for antiinfectives (“irrational” is an acceptable answer).
f. Fluconazole to raise tacrolimus levels, or erythromycin for gastric motility, or similar non anti-infective use of
anti-infective drug.
7. Is there a date certain stop date for this anti-infective? Answer Y/N in DtCert column.
Drug

Indication

Organism (if indication is C)

DtCert (Y/N)

